Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
about
Membranous nephropathy: a retrospective observational study of membranous nephropathy in north east and central London.The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome.Pharmacological treatment of primary membranous nephropathy in 2016.Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab.Overview of current and alternative therapies for idiopathic membranous nephropathy.Monoclonal antibodies for renal diseases: current concepts and ongoing treatments.Membranous nephropathy: thinking through the therapeutic options.Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis.Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.Treatment of membranous nephropathy: time for a paradigm shift.Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.Malignancy in Membranous Nephropathy: Evaluation of Incidence.Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy.Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy.Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide.Malignancy in Renal Transplant Recipients Exposed to Cyclophosphamide Prior to Transplantation for the Treatment of Native Glomerular Disease.A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis.Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.Regulatory verification on safe use of cytotoxic drugs in veterinary clinics and animal hospitals.Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.Pharmacotherapy options for membranous nephropathy
P2860
Q33823525-F610EE14-34A5-44F6-A989-71778DCAB30BQ36098017-F60FBC42-1F43-4246-AC34-37FD620FD162Q36106413-10133997-F140-4DF3-8429-0AA3ABB0D976Q36265388-90DCD6B0-BAF0-4DFE-938D-302B42B9DCC4Q36296621-5DB36162-C2F8-40A6-A869-E989AED26019Q37475696-449CF317-1D79-4199-A028-DECFBADC525BQ38425865-0C9FAD4C-5060-4808-A8CA-F32E0BCD2A61Q38531349-9B91D19A-A9E1-49AB-807F-36EED4812025Q38733002-EFDFEFEB-CFEB-4E18-929C-A596AB2E2956Q39022568-513E2AB0-2E13-4145-A3BE-50927156F78CQ39335899-DB68C064-D9BE-4ACD-B674-0BB02E6C8D7CQ39410091-BA861FB5-E38A-4282-BFF3-358390961CE9Q40208466-58AA144F-2BEA-4C75-A4E7-75A8EDFFF5A6Q41169077-8CA1D579-6B1F-4146-B50D-A75870C5BD90Q42113573-8A397B40-D5A7-44E5-BA56-171497BC78C2Q42639047-2F2840FA-6F18-4AB4-AEFC-31C5591786FDQ45348164-5E32762F-E4FB-42DD-AE64-3AB9DF2B89C5Q47599071-3982AFE3-6FE5-492E-BA44-BA5225AAB7AFQ53324683-20339CD6-1200-41C7-A3A6-5438D29F8A35Q53410936-889E9826-8429-4310-94BF-F25DCC22ADCDQ53751411-F34877B8-D03F-4D2F-96E6-A441C7E8FFD6Q55191066-00D8E333-E848-452C-B55B-361A489F8C7BQ57701454-F67F490A-43C7-4964-AC82-6F64E3EE37A5
P2860
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
@ast
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
@en
type
label
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
@ast
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
@en
prefLabel
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
@ast
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
@en
P2093
P2860
P356
P1476
Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.
@en
P2093
Jack F M Wetzels
Jan A J G van den Brand
Julia M Hofstra
Peter R van Dijk
P2860
P304
P356
10.2215/CJN.08880813
P577
2014-05-22T00:00:00Z